Détail de l'auteur
Auteur M. HICKMAN
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Faire une suggestion Affiner la recherche
Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database / R. CORNISH ; J. MACLEOD ; J. STRANG ; P. VICKERMAN ; M. HICKMAN in British Medical Journal, Vol.341, n°7779 (30 October 2010)
Titre : Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database Type de document : Périodique Auteurs : R. CORNISH ; J. MACLEOD ; J. STRANG ; P. VICKERMAN ; M. HICKMAN Année de publication : 2010 Article en page(s) : c5475 ; 8 p. Note générale : Article analysé en français dans le Flyer n°42, p.20-21. Langues : Anglais (eng) Mots-clés : Thésaurus Géographique
TRAITEMENT DE MAINTENANCE ; SUBSTITUTION ; FACTEUR DE RISQUE ; MORTALITE ; ETUDE PROSPECTIVE
Discipline : TRA Traitement et prise en charge / Treatment and care Résumé : Objective To investigate the effect of opiate substitution treatment at the beginning and end of treatment and according to duration of treatment.
Design Prospective cohort study.
Setting UK General Practice Research Database
Participants Primary care patients with a diagnosis of substance misuse prescribed methadone or buprenorphine during 1990-2005. 5577 patients with 267 003 prescriptions for opiate substitution treatment followed-up (17 732 years) until one year after the expiry of their last prescription, the date of death before this time had elapsed, or the date of transfer away from the practice.
Main outcome measures Mortality rates and rate ratios comparing periods in and out of treatment adjusted for sex, age, calendar year, and comorbidity; standardised mortality ratios comparing opiate users’ mortality with general population mortality rates.
Results Crude mortality rates were 0.7 per 100 person years on opiate substitution treatment and 1.3 per 100 person years off treatment; standardised mortality ratios were 5.3 (95% confidence interval 4.0 to 6.8) on treatment and 10.9 (9.0 to 13.1) off treatment. Men using opiates had approximately twice the risk of death of women (morality rate ratio 2.0, 1.4 to 2.9). In the first two weeks of opiate substitution treatment the crude mortality rate was 1.7 per 100 person years: 3.1 (1.5 to 6.6) times higher (after adjustment for sex, age group, calendar period, and comorbidity) than the rate during the rest of time on treatment. The crude mortality rate was 4.8 per 100 person years in weeks 1-2 after treatment stopped, 4.3 in weeks 3-4, and 0.95 during the rest of time off treatment: 9 (5.4 to 14.9), 8 (4.7 to 13.7), and 1.9 (1.3 to 2.8) times higher than the baseline risk of mortality during treatment. Opiate substitution treatment has a greater than 85% chance of reducing overall mortality among opiate users if the average duration approaches or exceeds 12 months.
Conclusions Clinicians and patients should be aware of the increased mortality risk at the start of opiate substitution treatment and immediately after stopping treatment. Further research is needed to investigate the effect of average duration of opiate substitution treatment on drug related mortality. [Author's abstract]
Domaine : Drogues illicites / Illicit drugs Refs biblio. : 41 Affiliation : School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, United Kingdom / Royaume-Uni Permalink :
in British Medical Journal > Vol.341, n°7779 (30 October 2010) . - c5475 ; 8 p.[article]Scaling-up HCV prevention and treatment interventions in rural United States - model projections for tackling an increasing epidemic / H. FRASER ; J. ZIBBELL ; T. HOERGER ; S. HARIRI ; C. VELLOZZI ; N. K. MARTIN ; A. H. KRAL ; M. HICKMAN ; J. W. WARD ; P. VICKERMAN in Addiction, Vol.113, n°1 (January 2018)
Titre : Scaling-up HCV prevention and treatment interventions in rural United States - model projections for tackling an increasing epidemic Type de document : Périodique Auteurs : H. FRASER ; J. ZIBBELL ; T. HOERGER ; S. HARIRI ; C. VELLOZZI ; N. K. MARTIN ; A. H. KRAL ; M. HICKMAN ; J. W. WARD ; P. VICKERMAN Année de publication : 2018 Article en page(s) : 173-182 Note générale : Commentary: Evidence base for harm reduction services - the urban-rural divide. Lancaster K.E., Malvestutto C.D., Miller W.C., Go V.F., p. 183-184. Langues : Anglais (eng) Mots-clés : Thésaurus Géographique
HEPATITE ; PREVENTION ; REDUCTION DES RISQUES ; USAGER ; MILIEU RURAL ; MODELE STATISTIQUE ; EPIDEMIOLOGIE ; INFECTION
Discipline : MAL Maladies infectieuses / Infectious diseases Résumé : Background and aims: Effective strategies are needed to address dramatic increases in hepatitis C virus (HCV) infection among people who inject drugs (PWID) in rural settings of the United States. We determined the required scale-up of HCV treatment with or without scale-up of HCV prevention interventions to achieve a 90% reduction in HCV chronic prevalence or incidence by 2025 and 2030 in a rural US setting.
Design: An ordinary differential equation model of HCV transmission calibrated to HCV epidemiological data obtained primarily from an HIV outbreak investigation in Indiana.
Setting: Scott County, Indiana (population 24 181), USA, a rural setting with negligible baseline interventions, increasing HCV epidemic since 2010, and 55.3% chronic HCV prevalence among PWID in 2015.
Measurements: Required annual HCV treatments per 1000 PWID (and initial annual percentage of infections treated) to achieve a 90% reduction in HCV chronic prevalence or incidence by 2025/30, either with or without scaling-up syringe service programmes (SSPs) and medication-assisted treatment (MAT) to 50% coverage. Sensitivity analyses considered whether this impact could be achieved without re-treatment of re-infections, and whether greater intervention scale-up was required due to the increasing epidemic in this setting.
Findings: To achieve a 90% reduction in incidence and prevalence by 2030, without MAT and SSP scale-up, 159 per 1000 PWID (initially 24.9% of infected PWID) need to be HCV-treated annually. However, with MAT and SSP scaled-up, treatment rates are halved (89 per 1000 annually or 14.5%). To reach the same target by 2025 with MAT and SSP scaled-up, 121 per 1000 PWID (19.9%) need treatment annually. These treatment requirements are threefold higher than if the epidemic was stable, and the impact targets are unattainable without retreatment.
Conclusions: Combined scale-up of hepatitis C virus treatment and prevention interventions is needed to decrease the increasing burden of hepatitis C virus incidence and prevalence in rural Indiana, USA, by 90% by 2025/30.
Domaine : Drogues illicites / Illicit drugs Refs biblio. : 61 Affiliation : Social and Community Medicine, University of Bristol, Bristol, UK Cote : Abonnement Permalink :
in Addiction > Vol.113, n°1 (January 2018) . - 173-182[article]A systematic review of injecting-related injury and disease among people who inject drugs / S. LARNEY ; A. PEACOCK ; B. M. MATHERS ; M. HICKMAN ; L. DEGENHARDT in Drug and Alcohol Dependence, Vol.171 (February 2017)
Titre : A systematic review of injecting-related injury and disease among people who inject drugs Type de document : Périodique Auteurs : S. LARNEY ; A. PEACOCK ; B. M. MATHERS ; M. HICKMAN ; L. DEGENHARDT Année de publication : 2017 Article en page(s) : 39-49 Langues : Anglais (eng) Mots-clés : Thésaurus TOXIBASE
INJECTION ; FACTEUR DE RISQUE ; USAGER ; VOIE INTRAVEINEUSE ; ABCES ; ENDOCARDITE ; INFECTION ; PEAU
Discipline : PAT Pathologie organique / Organic pathology Résumé : Background: Non-viral injecting-related injuries and diseases (IRID), such as abscesses and vascular damage, can result in significant morbidity and mortality if untreated. There has been no systematic assessment of the prevalence of non-viral IRID among people who inject drugs; this review aimed to address this gap, as well as identify risk factors for experience of specific IRID.
Methods: We searched MEDLINE, Embase and CINAHL databases to identify studies on the prevalence of, or risk factors for, IRID directly linked to injecting in samples of people who inject illicit drugs.
Results: We included 33 studies: 29 reported IRID prevalence in people who inject drugs, and 17 provided data on IRID risk factors. Skin and soft tissue infections at injecting sites were the most commonly reported IRID, with wide variation in lifetime prevalence (6-69%). Female sex, more frequent injecting, and intramuscular and subcutaneous injecting appear to be associated with skin and soft tissue infections at injecting sites. Cleaning injecting sites was protective against skin infections. Other IRID included infective endocarditis (lifetime prevalence ranging from 0.5-12%); sepsis (2-10%); bone and joint infections (0.5-2%); and thrombosis and emboli (3-27%).
Conclusions: There were significant gaps in the data, including a dearth of research on prevalence of IRID in low- and middle-income countries, and potential risk and protective factors for IRID. A consistent approach to measurement, including standardised definitions of IRID, is required for future research.
Skin and soft tissue infections are common among people who inject drugs.
There are few data on other injecting-related injuries and diseases.
Cleaning injecting sites and avoiding intramuscular and subcutaneous injecting may reduce injecting-related injury and disease (IRID) risk.
Better epidemiological data are needed to inform prevention and care interventions.
Domaine : Drogues illicites / Illicit drugs Sous-type de document : Revue de la littérature / Literature review Affiliation : National Drug and Alcohol Research Centre, UNSW Australia, Sydney, Australia Permalink :
in Drug and Alcohol Dependence > Vol.171 (February 2017) . - 39-49[article]The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence / K. M. E. TURNER ; S. HUTCHINSON ; P. VICKERMAN ; V. HOPE ; N. CRAINE ; N. E. PALMATEER ; M. MAY ; A. TAYLOR ; D. DE ANGELIS ; S. CAMERON ; J. PARRY ; M. LYONS ; D. GOLDBERG ; E. ALLEN ; M. HICKMAN in Addiction, Vol.106, n°11 (November 2011)
Titre : The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence Titre traduit : (L'impact de la fourniture d'aiguilles et de seringues et d'une thérapie de substitution sur l'incidence du virus de l'hépatite C chez les usagers de drogue injecteurs : mise en commun des preuves au Royaume-Uni) Type de document : Périodique Auteurs : K. M. E. TURNER ; S. HUTCHINSON ; P. VICKERMAN ; V. HOPE ; N. CRAINE ; N. E. PALMATEER ; M. MAY ; A. TAYLOR ; D. DE ANGELIS ; S. CAMERON ; J. PARRY ; M. LYONS ; D. GOLDBERG ; E. ALLEN ; M. HICKMAN Année de publication : 2011 Article en page(s) : 1978-1988 Note générale : • Commentary: Significant global scale-up of harm reduction interventions and pragmatic research approaches needed to prevent hepatitis C transmission. Day C., Topp L., p. 1989-1990.
• Analyse : "Impact des pratiques d'injection sur l'incidence de l'hépatite C chez les usagers de drogue", Lert F. Swaps, 2012, n°69, p. 13-14.
Langues : Anglais (eng) Mots-clés : Thésaurus Géographique
PROGRAMME ; ECHANGE DE SERINGUES ; HEPATITE ; USAGER ; INJECTION ; TRAITEMENT DE MAINTENANCE ; SUBSTITUTION ; METHADONE ; PREVENTION PRIMAIRE ; REDUCTION DES RISQUES ; INCIDENCE
Discipline : MAL Maladies infectieuses / Infectious diseases Résumé : AIMS To investigate whether opiate substitution therapy (OST) and needle and syringe programmes (NSP) can reduce hepatitis C virus (HCV) transmission among injecting drug users (IDUs).
DESIGN Meta-analysis and pooled analysis, with logistic regression allowing adjustment for gender, injecting duration, crack injecting and homelessness.
SETTING Six UK sites (Birmingham, Bristol, Glasgow, Leeds, London and Wales), community recruitment.
PARTICIPANTS A total of 2986 IDUs surveyed during 2001-09.
MEASUREMENT Questionnaire responses were used to define intervention categories for OST (on OST or not) and high NSP coverage (>=100% versus FINDINGS Preliminary meta-analysis showed little evidence of heterogeneity between the studies on the effects of OST (I² = 48%, P = 0.09) and NSP (I² = 0%, P = 0.75), allowing data pooling. The analysis of both interventions included 919 subjects with 40 new HCV infections. Both receiving OST and high NSP coverage were associated with a reduction in new HCV infection [adjusted odds ratios (AORs) = 0.41, 95% confidence interval (CI): 0.21-0.82 and 0.48, 95% CI: 0.25-0.93, respectively]. Full harm reduction (on OST plus high NSP coverage) reduced the odds of new HCV infection by nearly 80% (AOR = 0.21, 95% CI: 0.08-0.52). Full harm reduction was associated with a reduction in self-reported needle sharing by 48% (AOR 0.52, 95% CI: 0.32-0.83) and mean injecting frequency by 20.8 injections per month (95% CI: -27.3 to -14.4).
CONCLUSIONS There is good evidence that uptake of opiate substitution therapy and high coverage of needle and syringe programmes can substantially reduce the risk of hepatitis C virus transmission among injecting drug users. Research is now required on whether the scaling-up of intervention exposure can reduce and limit hepatitis C virus prevalence in this population.
Domaine : Drogues illicites / Illicit drugs Refs biblio. : 46 Affiliation : School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom Cote : Abonnement Lien : http://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.2011.03515.x/abstract Permalink :
in Addiction > Vol.106, n°11 (November 2011) . - 1978-1988[article]The prevalence and management of co-morbid substance misuse and mental illness : results of a screening survey in substance misuse and mental health treatment populations / T. WEAVER
Titre : The prevalence and management of co-morbid substance misuse and mental illness : results of a screening survey in substance misuse and mental health treatment populations Titre traduit : (Prévalence et prise en charge des comorbidités de pathologies mentales et d'abus de substances : résultats d'une étude de populations en traitement pour problèmes psychiatriques ou en traitement pour abus de drogues) Type de document : Périodique Auteurs : T. WEAVER ; M. HICKMAN ; RUTTER D. ; J. WARD ; G. STIMSON ; A. RENTON Année de publication : 2001 Importance : 407-416 Présentation : tabl. Note générale : Drug and Alcohol Review, 2001, 20, (4), 407-416 Langues : Anglais (eng) Mots-clés : Thésaurus TOXIBASE
ABUS ; DEPENDANCE ; PSYCHOPATHOLOGIE ; COMORBIDITE ; TRAITEMENT ; PRISE EN CHARGE ; COMPARAISON ; PREVALENCE
A cross-sectional survey of clinical staff was carried out among statutory (public sector) substance misuse services and community mental health teams (CMHTs) in an inner London borough. We identified 368 current patients of drug and alcohol misuse services and 930 current patients of CNMTs. We measured the prevalence of co-morbid substance misuse and mental illness among these patients. We found strong evidence of co-morbid mental health problems in 128 substance misuse patients (34.8%) and evidence of possible co-morbidity in a further 18.5% of cases. Among mental health service patients, 227 (24%) were reported to have current substance misuse problems. Shared care of patients was uncommon and only a minority of co-morbid patients received treatment for both problems or the specialist assessment which key workers felt they needed. The findings suggest that co-morbidity is highly prevalent among mental health and substance misuse patients. Further research is needed to corroborate these findings, but the development and provision of evidence-based treatment and service interventions is likely to become increasing priority.(Author's abstract.)
Note de contenu : tabl. Domaine : Drogues illicites / Illicit drugs Refs biblio. : 36 Affiliation : Dept Soc. Sci. Med., Imperial Coll. Sci., Charing Cross Campus, St Dunstan's Rd, London W6 8RP
Royaume-Uni. United Kingdom.
Numéro Toxibase : 803907 Centre Emetteur : 08 CAS Strasbourg Permalink : The prevalence of injecting drug use in a Russian city: implications for harm reduction and coverage / L. PLATTPermalink"Trapping" in drug use and sex work careers / CUSICK L.PermalinkTrends in drug overdose deaths in England and Wales 1993-98: methadone does not kill more people than heroin / M. HICKMAN ; P. MADDEN ; J. HENRY ; A. BAKER ; C. WALLACE ; J. WAKEFIELD ; G. STIMSON ; P. ELLIOTT in Addiction, Vol.98, n°4 (April 2003)PermalinkValidating estimates of problematic drug use in England / M. FRISHER in BMC Public Health, Vol.7 n°286 (2007)PermalinkVol.47 - September 2017 - Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy (Bulletin de International Journal of Drug Policy) / J. GREBELY ; J. BRUNEAU ; P. BRUGGMANN ; M. HARRIS ; M. HICKMAN ; T. RHODES ; C. TRELOARPermalinkWhat is needed in future drug treatment research? A systematic approach to identify gaps on effectiveness of drug treatment from the EMCDDA / M. FERRI ; A. BO ; L. AMATO ; I. C. GUEDES ; C. S. ESTEVES ; L. WIESSING ; S. OLIVER ; M. HICKMAN ; M. DAVOLI in Drugs: Education, Prevention and Policy, Vol.22, n°1 (February 2015)Permalink